GAFFI RECOGNISES WORLD AIDS DAY BY APPLYING FOR ITRACONAZOLE TO BE INCLUDED ON ESSENTIAL MEDICINES LIST
Pioneering health charity GAFFI (Global Action Fund for Fungal Infections) is today* calling on the World Health Organisation (WHO) to help hundreds of thousand of AIDS and HIV positive patients worldwide by including itraconazole on the Essential Medicine List.
GAFFI’s application to WHO, in collaboration with the International Foundation for Dermatology, pinpoints key fungal diseases in AIDS for which itraconazole is crucial. Itraconazole suspension is ~70% effective for fluconazole oral thrush, and is the treatment of choice for eosinophilic folliculitis, a debilitating, itchy rash associated with HIV infection. Patients with Talaromyces marneffei infection (previously called penicilliosis) and common in SE Asia, also respond really well to itraconazole, as do those with coccidioidomycosis and paracoccidioidomycosis in the Americas. Numerous skin fungal infections in adults and children with HIV infection are not adequately treated with the drug, griseofulvin, which remains on the EML.
Dr David Denning, President of GAFFI and Professor of Infectious Disease in Global Health at The University of Manchester explained: “Every two years WHO calls for revision to the EML, and the deadline is today – World AIDS Day (December 1*). It is remarkable that such a workhorse antifungal such as itraconazole, which has been available since 1991, has not been included on the EML previously. Registered in most countries, itraconazole will provide the first effective oral antifungal for mould infections and endemic mycoses such as histoplasmosis.”
Professor Rod Hay of the International Foundation for Dermatology stated: “Itraconazole is a highly effective oral antifungal for many skin, hair and nail fungal infections. These are more problematic in HIV infected people, and so the inclusion of itraconazole on the EML will benefit huge numbers of adults and children with these infections. Given that nearly 1 billion people have skin fungal infection, and at least 200 million children, the potential impact of this development is enormous.”
The availability and cost of itraconazole in most countries is shown on these maps and demonstrates the gaps in access to antifungal treatments: www.gaffi.org/why/burden-of-disease-maps/ Itraconazole is available and approved in most countries, but not all, notably Senegal, Algeria, Afghanistan, Barbados, and Eritrea. It is approved in Dominican Republic, Iraq, Nepal and Ukraine, but not available.
Please contact Susan Osborne, Director of Communications at The Goodwork Organisation, on 07836 229208.
Global Action Fund for Fungal Infections (GAFFI) is an international foundation based in Geneva focussed on improving the survival and health of those with serious fungal infections, through universal access to diagnosis and treatment. GAFFI’s efforts are through advocacy, estimating the national burden of disease in each country and health professional education. Demonstration projects are planned in Kenya and Guatemala, and improved diagnostics are in development. www.gaffi.org Amongst GAFFI’s priority diseases, are histoplasmosis and chronic pulmonary aspergillosis for which itraconazole is a key antifungal. Fluconazole, which is on the EML, has no activity in aspergillosis and is inferior to fluconazole for histoplasmosis, a fungus that lives in the environment.
The International Foundation for Dermatology was established to improve the care of patients with skin disease, sexually transmitted infections and Leprosy in underserved areas of the world.